002737 Sunflower Pharmaceutical’s launch date will be announced on Tuesday, December 30, 2014

Sunflower Pharmaceutical Group is a large national pharmaceutical enterprise group with 14 companies under its jurisdiction. A well-known pharmaceutical group in the patent medicine industry, formerly known as Heilongjiang Sunflower Pharmaceutical Co., Ltd., after years of development, it has become a well-known pharmaceutical brand throughout the country. The "Sunflower" trademark has been recognized as a "China Famous Trademark" by the country. At the same time, It has been widely recognized by ordinary people and enjoys a high reputation in the minds of the masses

Sunflower Pharmaceutical Group was established by its flagship enterprise, Heilongjiang Sunflower Pharmaceutical Co., Ltd., through continuous development and growth of. It has jurisdiction over nine pharmaceutical manufacturing enterprises including Wuchang Sunflower, Yichun Sunflower, Chongqing Sunflower, Jiamusi Sunflower, Jiamusi (Luling) Sunflower, Tangshan Sunflower, Hengshui Sunflower, Hengshui (Jizhou) Sunflower, and Harbin Sunflower, two pharmaceutical companies, and one medicinal material cultivation company. The base includes a pharmaceutical packaging material company, a large pharmacy, and 14 enterprises, with total assets of 1.572 billion yuan and a total area of ??nearly one million square meters. The headquarters is located in Harbin. Chairman and President Guan Yanbin is a national model worker, a representative of the 11th National People's Congress, and the executive vice president of the All-China Federation of Industry and Commerce Pharmaceutical Chamber of Commerce.

The group’s main business is mainly Chinese patent medicines, and also covers chemical drugs and biological drugs. It integrates drug manufacturing, marketing, and scientific research. ***It has 15 dosage forms including tablets, pills, powders, suppositories, capsules, mixtures, granules, syrups, ointments, extracts, and sprays. At present, it has formed a series of hepatobiliary medications represented by Hugan Tablets, a series of gastrointestinal medications represented by Weikangling and Mesalazine Enteric-coated Tablets, and a series of medications represented by Children's Feire Kechuan Oral Liquid and Children's Huatan Zhike Granules. Xiaokuihua children's medication series, gynecological medication series represented by Kangfu Xiaoyan Suppository and Gengnian'an Tablets, rheumatism and bone disease medication series represented by Shuanghu Zhongtongning Spray and Modified Gastrodia Capsules, compound aminophenol alkylamine The Sunflower Blue Ren respiratory and cold medication series represented by Granules and Ganmao Qingre Granules, the cardiovascular and cerebrovascular medication series represented by Buxu Tongyu Granules and Tongmai Granules, and the antibiotic medication series represented by Cefaclor Granules and Amoxicillin Capsules The new product pattern includes 8 major series and 724 quasi-branded drugs, including 3 national protected traditional Chinese medicine varieties, 12 domestic exclusive varieties, and 181 products included in the National Essential Medicines List.